TPS Treatment for Alzheimer’s disease

Transcranial Pulse Stimulation (TPS) – Indication: Alzheimer’s disease

Alzheimer’s disease is the most common form of this neurodegenerative disease, accounting for around 65 percent of dementia cases. According to statistics from the organization Alzheimer’s Disease International, around 55 million people worldwide (as of 2023) suffer from dementia and, accordingly, over 42 million from the Alzheimer’s variant. By 2050, the number of people affected worldwide is expected to rise to 153 million, of whom almost 100 million will be affected by Alzheimer’s disease.

Alzheimer’s dementia, like all the other diseases described here, is not yet curable and its causes and development are not yet fully understood by scientists. Pharmaceutical treatment approaches to date are aimed at slowing down the progression of the disease, although breakthroughs are still to come.

TPS Treatment for Alzheimer’s disease: Goals and possibilities of TPS therapy

The treatment of Alzheimer’s dementia with Transcranial Pulse Stimulation (TPS) has shown in recent years, both in research and in practice, that the shock wave procedure is able to slow down or stop the progression of the disease, in some cases significantly, and improve the quality of life of patients to varying degrees. These include an increase in neuroplasticity and neurogenesis, an improvement in executive functions, orientation and initiative, as well as a reduction in word-finding disorders and dementia-associated depression. Initially only used for mild to moderate Alzheimer’s dementia, off-label therapy is now also used to treat very advanced and severe Alzheimer’s disease. Here too, treatment with TPS can have positive effects in relation to the disease state.